NEW DELHI: Pune-based
Krsnaa Diagnostics
, an integrated
diagnostics
provider, announced plans to acquire nearly 24% stake in start-up
Apulki Healthcare
for exclusive rights to provide diagnostics services.
Apulki Healthcare, incorporated in 2022, is engaged in establishing, operating and maintaining hospitals, focusing on
oncology
and
cardiology
, primarily under the public-private partnership mode, says a company statement.
The acquisition will be completed within the next three months.
Under this collaboration, Krsnaa Diagnostics will become the exclusive diagnostics partner for Apulki’s state-of-the-art cancer and cardiac hospitals for the next 30+ years. This ensures Krsnaa’s sustained leadership in the high-growth oncology and cardiac diagnostic segments, with access to Apulki’s planned network of 10+ hospitals across India.
By offering a comprehensive suite of cutting-edge diagnostic technologies—including MRI, PET CT, Cardiac CT, and Advanced Pathology—available 24×7 under one roof, Krsnaa and Apulki will provide seamless, world-class diagnostic services for patients undergoing cancer and cardiac treatment.
